Relatlimab (OPDUALAGTM, mAbID 781), recently approved by FDA in 2022, binds to LAG3 overexpressed by T cells in the TME and blocks its binding to its ligands, activating exhausted T cells and enhancing the CTL-mediated immune response against tumor cells (63) (Figure 6). This evidence concerns the gene LAG3 and neoplasm.